Inflammatory Disease

4
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Celltrion
CelltrionKorea - Incheon
1 program
1
Infliximab subcutaneousPhase 31 trial
Active Trials
NCT06059989RecruitingEst. Dec 2025
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
Lanraplenib.Phase 11 trial
Lanraplenib.Phase 1
Active Trials
NCT02959138Completed36Est. Oct 2018
Holoclara
HoloclaraCA - Los Angeles
1 program
1
HC002 SADPhase 11 trial
Active Trials
NCT06670274CompletedEst. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CelltrionInfliximab subcutaneous
HoloclaraHC002 SAD
Gilead SciencesLanraplenib.

Clinical Trials (3)

Total enrollment: 36 patients across 3 trials

NCT06059989CelltrionInfliximab subcutaneous

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

Start: Nov 2021Est. completion: Dec 2025
Phase 3Recruiting
NCT06670274HoloclaraHC002 SAD

A Dose Escalating Study of HC002 in Healthy Adult Volunteers

Start: Nov 2024Est. completion: May 2025
Phase 1Completed
NCT02959138Gilead SciencesLanraplenib.

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

Start: Nov 2016Est. completion: Oct 201836 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 36 patients
3 companies competing in this space